Melt extrusion for the pharmaceutical industry
Two companies have recently agreed to cooperate on the further development of melt extrusion for the pharmaceutical industry: Thermo Fisher Scientific Inc., Waltham, USA, and Pharma Polymers, a division of Evonik Industries AG, Essen, Germany. The aim is to overcome the process limits in pharmaceutical development, such as improving the bioavailability of active ingredients and shortening the development time for drugs. In the pharmaceutical sector, melt extrusion in this context involves incorporating a drug in a polymeric substrate, with the simultaneous shaping of the composite material. This process is intended to ensure the bioavailability of the active ingredient and, at the same time, to mask its taste. Compared with other methods, the individual steps of melting, mixing, kneading, venting and extrusion are all combined in a permanent extrusion process. Pharma Polymers is contributing the polymer type, Eudragit, to the joint work, while Thermo Fisher Scientific is specialized in measurement technology for the laboratory and processing industry.
Patents encourage innovation: Stay on the ball with the latest innovations in the plastics industry in our patents section.
Would you like to subscribe to our Newsletters on plastics technology and profit from the latest information?
You know the trade name but want to know the material manufacturer, type of polymer and delivery form? Search here!